ARCT

Arcturus Therapeutics Holdings Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 2/10
  • Value↑ 10/10
Arcturus Therapeutics Holdings sales and earnings growth
ARCT Growth
Fair
  • Revenue Y/Y↓ -46.14%
  • EPS Y/Y↑ 20.00%
  • FCF Y/Y↓ -23.36%
Arcturus Therapeutics Holdings gross and profit margin trends
ARCT Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -80.20%
  • ROIC 5Y↓ -185.51%
Arcturus Therapeutics Holdings net debt vs free cash flow
ARCT Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Arcturus Therapeutics Holdings stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗